Following our meeting on September 20th, 2017, we actively explored the options to use the stock of human recombinant insulin that xxxx purchased from xxxxx after the discontinuation of your alliancepartnership with them.
After a thorough evaluation of all criteria, the xxxxx management chose to decline the option to buy this stock.
We thank you again for the clear explanations you have provided to us and for having offered this opportunity to Amphastar.
The text above was approved for publishing by the original author.
只需要到您的收件箱，点击我们的确认链接，您将得到正确的信息。如果您希望更正更多的电子邮件，只需要简单的：
或